Pembrolizumab in HER2-Positive Gastric Cancer

被引：3

作者：

Janjigian, Yelena Y. ^{[1
]}

Kawazoe, Akihito ^{[2
]}

Bai, Yuxian ^{[3
]}

Xu, Jianming ^{[4
]}

Lonardi, Sara ^{[5
]}

Metges, Jean Phillipe ^{[6
]}

Yanez, Patricio ^{[7
]}

Wyrwicz, Lucjan S. ^{[8
]}

Shen, Lin ^{[9
]}

Ostapenko, Yuriy ^{[10
]}

Bilici, Mehmet ^{[11
]}

Chung, Hyun Cheol ^{[12
]}

Shitara, Kohei

Qin, Shukui ^{[13
]}

Van Cutsem, Eric ^{[14
]}

Tabernero, Josep ^{[15
]}

Luo, Suxia ^{[16
]}

Mahave, Mauricio ^{[17
]}

Tang, Yong ^{[18
]}

Lowery, Maeve ^{[19
]}

Monteiro, Maria M. F. ^{[20
]}

Xu, Linzhi ^{[21
]}

Shih, Chie-Schin ^{[21
]}

Sharan, Kanu P. ^{[21
]}

Bhagia, Pooja ^{[21
]}

Rha, Sun Young ^{[12
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10029 USA

[2] Natl Canc Hosp East, Kashiwa, Japan

[3] Harbin Med Univ Canc Hosp, Harbin, Peoples R China

[4] Fifth Med Ctr Peoples Liberat Army, Beijing, Peoples R China

[5] Ist Oncol Veneto, Padua, Italy

[6] Univ Hosp Brest, Brest, France

[7] James Lind Canc Res Ctr, Temuco, Chile

[8] Maria Sklodowska Curie Natl Canc Res Inst, Warsaw, Poland

[9] Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China

[10] Natl Canc Inst, Kiev, Ukraine

[11] Ataturk Univ, Erzurum, Turkiye

[12] Yonsei Canc Ctr, Seoul, South Korea

[13] Canc Ctr Peoples Liberat Army, Nanjing, Peoples R China

[14] Univ Hosp Gasthuisberg, Leuven, Belgium

[15] Vall dHebron Univ Hosp, Inst Oncol, Barcelona, Spain

[16] Henan Canc Hosp, Zhengzhou, Peoples R China

[17] Fdn Arturo Lopez Perez, Santiago, Chile

[18] Xinjiang Med Univ, Canc Hosp, Urumqi, Peoples R China

[19] Trinity St Jamess Canc Inst, Dublin, Ireland

[20] Inst Canc Ceara, Fortaleza, CE, Brazil

[21] Merck, Rahway, NJ USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2024年

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1056/NEJMc2408121

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pembrolizumab in HER2-Positive Gastric Cancer The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.

引用

页数：3

共 50 条

[1] Pembrolizumab in HER2-Positive Gastric Cancer
Janjigian, Yelena Y.
Kawazoe, Akihito
Bai, Yuxian
Xu, Jianming
Lonardi, Sara
Metges, Jean Phillipe
Yanez, Patricio
Wyrwicz, Lucjan S.
Shen, Lin
Ostapenko, Yuriy
Bilici, Mehmet
Chung, Hyun Cheol
Shitara, Kohei
Qin, Shukui
Van Cutsem, Eric
Tabernero, Josep
Luo, Suxia
Mahave, Mauricio
Tang, Yong
Lowery, Maeve
Monteiro, Maria M. F.
Xu, Linzhi
Shih, Chie-Schin
Sharan, Kanu P.
Bhagia, Pooja
Rha, Sun Young
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (14): : 1360 - 1362
[2] HER2-Positive Gastric Cancer
Demetriades, Haralabos
ANNALS OF SURGICAL ONCOLOGY, 2011, 18 : S190 - S191
[3] HER2-positive gastric cancer
Boku, Narikazu
GASTRIC CANCER, 2014, 17 (01) : 1 - 12
[4] HER2-Positive Gastric Cancer
Haralabos Demetriades
Annals of Surgical Oncology, 2011, 18 : 190 - 191
[5] HER2-positive gastric cancer
Narikazu Boku
Gastric Cancer, 2014, 17 : 1 - 12
[6] TrastuzumabIn HER2-Positive Metastatic Gastric Cancer
Jamie D. Croxtall
Kate McKeage
Drugs, 2010, 70 : 2259 - 2267
[7] Trastuzumab In HER2-Positive Metastatic Gastric Cancer
Croxtall, Jamie D.
McKeage, Kate
DRUGS, 2010, 70 (17) : 2259 - 2267
[8] Overcoming resistance in HER2-positive gastric cancer: a case report on the synergistic effect of pembrolizumab and trastuzumab
Gong, Ting
Ma, Qing
Ren, Yaoyao
Gu, Liyan
Lv, Hui
Zhong, Diansheng
ANNALS OF MEDICINE AND SURGERY, 2024, 86 (12): : 7334 - 7337
[9] Pembrolizumab in combination with trastuzumab for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer
Qureshi, Zaheer
Jamil, Abdur
Fatima, Eeshal
Altaf, Faryal
Siddique, Rimsha
Shah, Shivendra
ANNALS OF MEDICINE AND SURGERY, 2024, 86 (08): : 4647 - 4656
[10] Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer
Zhifei Li
Huan Zhao
Huihui Hu
Haili Shang
Yongjing Ren
Wenhui Qiu
Hao Su
Huifang Lyu
Xiaobing Chen
Chinese Journal of Cancer Research, 2024, 36 (03) : 306 - 321

← 1 2 3 4 5 →